Interpace Biosciences, Inc. (IDXG)

Every figure this model derived for IDXG, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 353,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 2,794,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 10,968,000 AssetsCurrent 2026-06-30
current liabilities 4,951,000 LiabilitiesCurrent 2026-06-30
equity 23,244,000 StockholdersEquity 2026-06-30
interest expense 168,000 InterestPaidNet 2025-12-31
ocf 4,457,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 36,143,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 19,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up IDXG on one particular measure came for.

RatioValue
cash operating margin12.89
current ratio2.22
current ratio reported2.22
deferred revenue growth-58.14
dilution pct76.09
ebit yoy-27.21
fcf margin11.35
growth cv3.21
interest cover24.8
operating margin11.53
owner earnings margin11.3
revenue growth-20.48
revenue growth per share-54.84
roic16.09
rule of 40-8.96
sbc pct revenue0.05

What to be careful about

What this model itself distrusts about IDXG's figures. Written by the derivation as it ran, not added afterwards.